Recently, new data from a few patients have been released from NKX-101 (NKG2D CAR-NK in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)) (3/5 patients achieved CR) and NKX-019 (CD19 CAR-NK in CD19+ B acute lymphocytic leukemia (ALL) and lymphoma) (5/6 patients in CR) (preliminary dose-finding data report, Nkarta, April 2022). Here, CD19 is linked to lymphoma.